CD8A and neoplasm: Consistently, tumor biopsies showed CD8+ T cell deficiency and exhaustion and PD-1 downregulation in BRAFi- or BRAFi/MEKi-resistant melanoma [72], and vemurafenib or vemurafenib/trametinib combination impaired T cell activation [51].